30.2 C
Vientiane
Thursday, September 11, 2025
spot_img
Home Blog Page 468

Cango Inc. Announces Completion of Secondary Acquisition and Appointment of New Leadership Team

HONG KONG, July 23, 2025 /PRNewswire/ — Cango Inc. (NYSE: CANG) today announced its transformation into a global Bitcoin miner with the appointment of a new Board of Directors (the “Board”) and senior management team with deep expertise in digital-asset infrastructure, finance, and energy investments.

On July 23, 2025, the Board appointed (i) Mr. Xin Jin as Chairman of the Board and Non-Executive Director, (ii) Mr. Peng Yu as CEO and Director, (iii) Mr. Chang-Wei Chiu as Director, (iv) Mr. Yongyi Zhang as CFO and (v) Mr. Simon Ming Yeung Tang as CIO To strengthen governance, the Board also appointed (i) Mr. Chi Ming Lee, Independent Director, as a member of the Compensation Committee and Nominating and Corporate Governance Committee, (ii) Mr. Yanjun Lin, Independent Director, as Chairman of the Compensation Committee and member of the Nominating and Corporate Governance Committee, and (iii) Mr. Haitian Lu as Chairman of the Nominating and Corporate Governance Committee and member of the Compensation Committee. The Board also accepted the resignations of Mr. Xiaojun Zhang as Director and Chairman, and Mr. Jiayuan Lin as CEO, Interim CFO, and Director. All changes are effective immediately.

Mr. Peng Yu, CEO and Director, commented, “This leadership team gives Cango the right mix of skills to execute our next phase of growth. Having successfully transformed into a Bitcoin miner, we have already made remarkable progress in the past 7 months by becoming one of the largest Bitcoin miners in the world. With a strong balance sheet and clear long-term vision, our collective experience will help us scale beyond the 50 EH/s already deployed, not only safeguarding but strategically growing our treasury of more than 4,000 Bitcoins to maximize shareholder value. We will begin developing sustainable, high-performance computing opportunities while strategically expanding upstream into dedicated power resources especially green energy that will create lasting value for shareholders and drive further growth.”

Mr. Xiaojun Zhang and Mr. Jiayuan Lin resigned as co-founders coinciding with a secondary sale of 10 million Class B shares to Enduring Wealth Capital Limited for US$70 million. They converted their remaining Class B shares into Class A shares, now holding 18.54% of total outstanding shares and 12.07% of voting power. Enduring Wealth Capital Limited now holds about 2.82% of outstanding shares and 36.73% of voting power..

Full article: https://ir-image.cangoonline.com/ir-documents/2025-07-23_Cango%20Inc.%20Announces%20Completion%20of%20Secondary%20Acquisition%20and%20Appointment%20of%20New%20Leadership%20Team.pdf

Investor Relations Contact

Juliet YE, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink’s operational rigor and readiness to meet evolving customer and regulatory demands

BOSTON, July 23, 2025 /PRNewswire/ — TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced the successful completion of its ISO 9001:2015 annual surveillance audit, expanding scope to include OPUS, the Orchestration Platform for Universal Solutions. The achievement reaffirms the company’s commitment to delivering high-quality, reliable, and continuously-improving solutions and platform capabilities for organizations in highly regulated industries, including life sciences, healthcare, and pharmaceuticals.

The ISO 9001:2015 certification, awarded following an extensive third-party audit by an accredited certification body, validates that TraceLink’s internal quality management system (QMS) meets the international standard’s rigorous requirements. This includes formalized processes for quality control, customer satisfaction, risk management, and continuous improvement across the organization.

A Trusted SaaS Partner for Regulated Industries
As companies in regulated industries look to modernize their operations with reliable and secure SaaS solutions, ISO 9001 certification provides customers with an added layer of assurance. TraceLink’s quality systems support scalability, governance, and operational risk mitigation, helping businesses meet their own compliance mandates, such as GxP, SOX, or ISO 27001 requirements.

“Expanding our ISO 9001 certification to include OPUS is a powerful affirmation of the reliability, repeatability, and quality-first processes that underpin TraceLink’s platform,” said Shabbir Dahod, President and CEO of TraceLink. “With more than 15 years of experience delivering solutions built to meet the rigor of GxP environments, customers can trust that everything from digital network integration to intelligent data and process orchestration is developed and supported under a robust, independently audited quality system. As OPUS evolves to meet increasingly complex supply chain needs—including agentic AI orchestration—it does so with the discipline and assurance of certified quality.”

Innovation Backed by Structured Quality
TraceLink’s certification reflects its process maturity in delivering no-code, cloud-based network digitalization capabilities via OPUS. Through robust internal audits, corrective action frameworks, and structured management reviews, TraceLink ensures that its platform innovation aligns with the highest standards of quality and reliability.

This expanded certification joins the portfolio of TraceLink’s global security and compliance achievements, including ISO/IEC 27001:2022, ISO/IEC 27017:2015, SOC 2 / ISAE 3000 Type II, and a top-tier rating from CyberVadis. Together, these certifications demonstrate TraceLink’s multi-dimensional leadership in safeguarding customer data, delivering dependable solutions, and meeting the compliance expectations of enterprise and public-sector buyers alike.

For more information on TraceLink’s certifications, visit tracelink.com/legal-and-trust/certifications-and-attestations.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

NEW YORK, July 23, 2025 /PRNewswire/ — Azure Knowledge Corporation, a global provider of high-quality market research data since 2000, today announced the rebranding of its research arm as Mavrix, marking a strategic evolution in the company’s identity and mission.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence
Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

The rebranding to Mavrix reflects the company’s transformation into a modern data acquisition and intelligence firm. Mavrix specializes in a comprehensive range of data collection methodologies, including Online Panels/Communities, Phone/CATI, Face-to-Face Interviewing, Qualitative Services, Expert Networks, and Custom Recruitment, powered by industry-leading AI-based data quality and visualization tools.

Strategic Evolution for Global Leadership

“This rebrand responds to today’s shifting market landscape,” said Mavrix CEO Rafal Gajdamowicz. “We’re positioning Mavrix as a forward-thinking leader while staying true to our core values: quality, innovation, partnership, and client-focused service.”

The company has a global presence with leadership and operational teams across the U.S., Canada, Europe, and Asia, operating on six continents. They offer 24/7 support, local expertise, and deliver projects in 85+ countries in 40+ languages.

Technology Meets Human Expertise

By combining cutting-edge AI tools with human insight, Mavrix manages complex, multi-country projects using a wide spectrum of methodologies — from online surveys and in-person interviews to immersive environments and qualitative research.

Over 300 organizations worldwide — from Fortune 500s to startups and research firms — trust Mavrix for tailored solutions across finance, tech, healthcare, and consumer goods.

“We focus on building long-term, sustainable partnerships with our clients,” said Neil Blefeld, Managing Director of North America for Mavrix. “Our clients don’t just receive data — they gain insights that drive real advantage.”

Seamless Transition Strategy

The rebrand is being implemented in phases to ensure a smooth and uninterrupted experience for all stakeholders. A new website and refreshed visual identity will spotlight Mavrix’s expanded capabilities and its leadership in data-driven innovation.

Vision for Continued Excellence

Mavrix is committed to delivering transformative impact over the next 25 years in an increasingly complex business environment. Its strategy is designed to lead the industry while upholding the high standards that have defined its legacy. “Our focus is on our clients — 100% — to continue delivering excellence through advanced technologies and research methodologies,” said Glen Collins, EVP – Global Commercial Group.

About Mavrix

Mavrix is a global data and intelligence company offering tech-enabled research solutions. Formerly part of Azure Knowledge, it blends advanced technology with human expertise to deliver quality data and insights worldwide. www.mavrixdata.com

TraceLink Updates ISO 9001 Certification to Support Scalable, Compliant Supply Chain Innovation

Independent audit confirms TraceLink’s operational rigor and readiness to meet evolving customer and regulatory demands

BOSTON, July 23, 2025 /PRNewswire/ — TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced the successful completion of its ISO 9001:2015 annual surveillance audit, expanding scope to include OPUS, the Orchestration Platform for Universal Solutions. The achievement reaffirms the company’s commitment to delivering high-quality, reliable, and continuously-improving solutions and platform capabilities for organizations in highly regulated industries, including life sciences, healthcare, and pharmaceuticals.

The ISO 9001:2015 certification, awarded following an extensive third-party audit by an accredited certification body, validates that TraceLink’s internal quality management system (QMS) meets the international standard’s rigorous requirements. This includes formalized processes for quality control, customer satisfaction, risk management, and continuous improvement across the organization.

A Trusted SaaS Partner for Regulated Industries
As companies in regulated industries look to modernize their operations with reliable and secure SaaS solutions, ISO 9001 certification provides customers with an added layer of assurance. TraceLink’s quality systems support scalability, governance, and operational risk mitigation, helping businesses meet their own compliance mandates, such as GxP, SOX, or ISO 27001 requirements.

“Expanding our ISO 9001 certification to include OPUS is a powerful affirmation of the reliability, repeatability, and quality-first processes that underpin TraceLink’s platform,” said Shabbir Dahod, President and CEO of TraceLink. “With more than 15 years of experience delivering solutions built to meet the rigor of GxP environments, customers can trust that everything from digital network integration to intelligent data and process orchestration is developed and supported under a robust, independently audited quality system. As OPUS evolves to meet increasingly complex supply chain needs—including agentic AI orchestration—it does so with the discipline and assurance of certified quality.”

Innovation Backed by Structured Quality
TraceLink’s certification reflects its process maturity in delivering no-code, cloud-based network digitalization capabilities via OPUS. Through robust internal audits, corrective action frameworks, and structured management reviews, TraceLink ensures that its platform innovation aligns with the highest standards of quality and reliability.

This expanded certification joins the portfolio of TraceLink’s global security and compliance achievements, including ISO/IEC 27001:2022, ISO/IEC 27017:2015, SOC 2 / ISAE 3000 Type II, and a top-tier rating from CyberVadis. Together, these certifications demonstrate TraceLink’s multi-dimensional leadership in safeguarding customer data, delivering dependable solutions, and meeting the compliance expectations of enterprise and public-sector buyers alike.

For more information on TraceLink’s certifications, visit tracelink.com/legal-and-trust/certifications-and-attestations.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

NEW YORK, July 23, 2025 /PRNewswire/ — Azure Knowledge Corporation, a global provider of high-quality market research data since 2000, today announced the rebranding of its research arm as Mavrix, marking a strategic evolution in the company’s identity and mission.

Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence
Azure Knowledge Corporation Rebrands as Mavrix to Drive AI-Powered Data Intelligence

The rebranding to Mavrix reflects the company’s transformation into a modern data acquisition and intelligence firm. Mavrix specializes in a comprehensive range of data collection methodologies, including Online Panels/Communities, Phone/CATI, Face-to-Face Interviewing, Qualitative Services, Expert Networks, and Custom Recruitment, powered by industry-leading AI-based data quality and visualization tools.

Strategic Evolution for Global Leadership

“This rebrand responds to today’s shifting market landscape,” said Mavrix CEO Rafal Gajdamowicz. “We’re positioning Mavrix as a forward-thinking leader while staying true to our core values: quality, innovation, partnership, and client-focused service.”

The company has a global presence with leadership and operational teams across the U.S., Canada, Europe, and Asia, operating on six continents. They offer 24/7 support, local expertise, and deliver projects in 85+ countries in 40+ languages.

Technology Meets Human Expertise

By combining cutting-edge AI tools with human insight, Mavrix manages complex, multi-country projects using a wide spectrum of methodologies — from online surveys and in-person interviews to immersive environments and qualitative research.

Over 300 organizations worldwide — from Fortune 500s to startups and research firms — trust Mavrix for tailored solutions across finance, tech, healthcare, and consumer goods.

“We focus on building long-term, sustainable partnerships with our clients,” said Neil Blefeld, Managing Director of North America for Mavrix. “Our clients don’t just receive data — they gain insights that drive real advantage.”

Seamless Transition Strategy

The rebrand is being implemented in phases to ensure a smooth and uninterrupted experience for all stakeholders. A new website and refreshed visual identity will spotlight Mavrix’s expanded capabilities and its leadership in data-driven innovation.

Vision for Continued Excellence

Mavrix is committed to delivering transformative impact over the next 25 years in an increasingly complex business environment. Its strategy is designed to lead the industry while upholding the high standards that have defined its legacy. “Our focus is on our clients — 100% — to continue delivering excellence through advanced technologies and research methodologies,” said Glen Collins, EVP – Global Commercial Group.

About Mavrix

Mavrix is a global data and intelligence company offering tech-enabled research solutions. Formerly part of Azure Knowledge, it blends advanced technology with human expertise to deliver quality data and insights worldwide. www.mavrixdata.com

Kelun-Biotech’s Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

Kelun-Biotech’s Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378

CHENGDU, China, July 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, HKEX: 6990) today announced that its partner, Windward Bio AG (“Windward Bio”) has launched its Phase 2 POLARIS clinical study, assessing long-acting dosing of SKB378/WIN378 for people living with asthma.

SKB378/WIN378 is a novel, recombinant fully human monoclonal antibody (mAb) that potently binds to the thymic stromal lymphopoietin (TSLP) ligand and inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor. This is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological conditions, including asthma and chronic obstructive pulmonary disease (COPD) where inhibition has demonstrated benefit in a wide array of inflammatory phenotypes. SKB378/WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered. SKB378/WIN378 has been studied in a Phase 1 trial which confirmed the half-life for extended dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest tested dose. 

The Phase 2 POLARIS trial is a global, randomized, double-blind, placebo-controlled study evaluating the dosing, safety, and efficacy of SKB378/WIN378 in patients with asthma. Initial data is expected in mid-2026. Additional clinical trials are planned with SKB378/WIN378 including in COPD in 2026. In January 2025, an IND application for SKB378/WIN378 for the treatment of COPD was approved by the National Medical Products Administration (NMPA).

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed (also known as HBM9378), with both parties equally sharing global rights. In January 2025, it was announced that the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specifics targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

NYSE Content Advisory: Pre-market update + NIQ to debut, NYSE joins AI Summit

NEW YORK, July 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. The NYSE is participating at the All In and Hill and Valley’s “Winning the AI Race” Summit, capturing insights from key voices shaping the future of business, technology, and innovation.  

 

NYSE Content Advisory: Pre-market update + NIQ to debut, NYSE joins AI Summit

Ashley Mastronardi delivers the pre-market update on July 23rd

  • Stocks are fractionally higher Wednesday morning after President Trump announced a “massive deal” with Japan. This move includes a reciprocal tariff of 15% on exports to the U.S. and Japan investing $550 Billion to the U.S.
  • Investors are also paying attention to a slew of earnings throughout the day including NYSE-listed telecommunications giant AT&T. Tesla and Alphabet headline earnings after market close.
  • Consumer intelligence company NielsenIQ celebrates its IPO at the NYSE this morning. The company, which raised over $1 billion, will ring the opening bell and begin trading under the ticker symbol NIQ.
  • The NYSE is participating in the All In and Hill & Valley “Winning the AI Race” Summit in Washington D.C., engaging with influential leaders and innovators to gather strategic insights on the evolving intersection of AI, business, and technology.  

Opening Bell
NielsenIQ (NYSE: NIQ) celebrates its initial public offering

Closing Bell
Gotham FC celebrates becoming the first American women’s pro soccer club to win a continental competition 

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2736810/NYSE_Market_Update_July_23.mp4